Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers.

Kidney cancer (Clifton, Va.) Pub Date : 2020-01-01 Epub Date: 2020-03-30 DOI:10.3233/kca-190072
Michael Siev, Audrey Renson, Hung-Jui Tan, Tracy L Rose, Stella K Kang, William C Huang, Marc A Bjurlin
{"title":"Prognostic Value of Histologic Subtype and Treatment Modality for T1a Kidney Cancers.","authors":"Michael Siev, Audrey Renson, Hung-Jui Tan, Tracy L Rose, Stella K Kang, William C Huang, Marc A Bjurlin","doi":"10.3233/kca-190072","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and curative treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN).</p><p><strong>Materials and methods: </strong>We queried the National Cancer Data Base (2004-2015) for patients with T1a kidney cancers who were treated surgically. OS was estimated by Kaplan-Meier curves based on histologic subtype and management. Cox proportional regression models were used to determine whether histologic subtypes and management procedure predicted OS.</p><p><strong>Results: </strong>46,014 T1a kidney cancers met inclusion criteria. Kaplan Meier curves demonstrated differences in OS by treatment for clear cell, papillary, chromophobe, and cystic histologic subtypes (all <i>p</i> < 0.001), but no differences for sarcomatoid (<i>p</i> = 0.110) or collecting duct (<i>p</i> = 0.392) were observed. Adjusted Cox regression showed worse OS for PA than PN among patients with clear cell (HR 1.58, 95%CI [1.44-1.73], papillary RCC (1.53 [1.34-1.75]), and chromophobe RCC (2.19 [1.64-2.91]). OS was worse for RN than PN for clear cell (HR 1.38 [1.28-1.50]) papillary (1.34 [1.16-1.56]) and chromophobe RCC (1.92 [1.43-2.58]). Predictive models using Cox proportional hazards incorporating histology and surgical procedure alone were limited (c-index 0.63) while adding demographics demonstrated fair predictive power for OS (c-index 0.73).</p><p><strong>Conclusions: </strong>In patients with pathologic T1a RCC, patterns of OS differed by surgery and histologic subtype. Patients receiving PN appears to have better prognosis than both PA and RN. However, the incorporation of histologic subtype and treatment modality into a risk stratification model to predict OS had limited utility compared with variables representing competing risks.</p>","PeriodicalId":74039,"journal":{"name":"Kidney cancer (Clifton, Va.)","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171275/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kidney cancer (Clifton, Va.)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/kca-190072","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/3/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: To evaluate overall survival (OS) of T1a kidney cancers stratified by histologic subtype and curative treatment including partial nephrectomy (PN), percutaneous ablation (PA), and radical nephrectomy (RN).

Materials and methods: We queried the National Cancer Data Base (2004-2015) for patients with T1a kidney cancers who were treated surgically. OS was estimated by Kaplan-Meier curves based on histologic subtype and management. Cox proportional regression models were used to determine whether histologic subtypes and management procedure predicted OS.

Results: 46,014 T1a kidney cancers met inclusion criteria. Kaplan Meier curves demonstrated differences in OS by treatment for clear cell, papillary, chromophobe, and cystic histologic subtypes (all p < 0.001), but no differences for sarcomatoid (p = 0.110) or collecting duct (p = 0.392) were observed. Adjusted Cox regression showed worse OS for PA than PN among patients with clear cell (HR 1.58, 95%CI [1.44-1.73], papillary RCC (1.53 [1.34-1.75]), and chromophobe RCC (2.19 [1.64-2.91]). OS was worse for RN than PN for clear cell (HR 1.38 [1.28-1.50]) papillary (1.34 [1.16-1.56]) and chromophobe RCC (1.92 [1.43-2.58]). Predictive models using Cox proportional hazards incorporating histology and surgical procedure alone were limited (c-index 0.63) while adding demographics demonstrated fair predictive power for OS (c-index 0.73).

Conclusions: In patients with pathologic T1a RCC, patterns of OS differed by surgery and histologic subtype. Patients receiving PN appears to have better prognosis than both PA and RN. However, the incorporation of histologic subtype and treatment modality into a risk stratification model to predict OS had limited utility compared with variables representing competing risks.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
T1a肾癌组织学亚型和治疗方式的预后价值
引言评估按组织学亚型和根治性治疗(包括肾部分切除术(PN)、经皮消融术(PA)和根治性肾切除术(RN))分层的T1a肾癌患者的总生存率(OS):我们查询了全国癌症数据库(2004-2015年)中接受手术治疗的T1a肾癌患者。根据组织学亚型和治疗方法,通过 Kaplan-Meier 曲线估算 OS。Cox比例回归模型用于确定组织学亚型和管理程序是否能预测OS:46,014例T1a肾癌符合纳入标准。卡普兰-梅尔曲线显示,透明细胞、乳头状、嗜铬细胞和囊性组织学亚型的OS在治疗方法上存在差异(均为p < 0.001),但肉瘤样癌(p = 0.110)或集合管癌(p = 0.392)则无差异。调整后的 Cox 回归显示,在透明细胞(HR 1.58,95%CI [1.44-1.73])、乳头状 RCC(1.53 [1.34-1.75])和嗜色素 RCC(2.19 [1.64-2.91])患者中,PA 的 OS 比 PN 差。对于透明细胞型(HR 1.38 [1.28-1.50])、乳头状型(1.34 [1.16-1.56])和嗜色细胞型 RCC(1.92 [1.43-2.58]),RN 的 OS 比 PN 差。仅使用包含组织学和手术方法的Cox比例危险度预测模型的预测能力有限(c-index 0.63),而加入人口统计学因素后,对OS的预测能力尚可(c-index 0.73):结论:在病理T1a RCC患者中,OS模式因手术和组织学亚型而异。与PA和RN相比,接受PN治疗的患者似乎预后更好。然而,与代表竞争风险的变量相比,将组织学亚型和治疗方式纳入风险分层模型以预测OS的效用有限。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Effectiveness of Second-Line Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma Patients After First-Line Treatment with Immune Checkpoint Inhibitor-based Combinations. Post-Metastasectomy Adjuvant Therapy in Patients with Renal Cell Carcinoma: A Systematic Review. Erratum to: Extended Disease Control with Unconventional Cabozantinib Dose Increase in Metastatic Renal Cell Carcinoma. A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1